
FOODMARBLE DIGESTIVE HEALTH LIMITED

ABRIDGED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

FOODMARBLE DIGESTIVE HEALTH LIMITED

COMPANY INFORMATION

Directors	Aonghus Shortt Peter Harte James Brief (United States) Stephen Burdock
Company secretary	Wilton Secretarial Limited
Registered number	574999
Registered office	Guinness Enterprise Centre Taylor's Lane Dublin 8
Independent auditors	Azets Audit Services Ireland Limited 3rd Floor 40 Mespil Road Dublin 4
Bankers	Allied Irish Bank Ballsbridge Dublin 2
Solicitors	McCann Fitzgerald LLP Sir John Rogerson's Quay Dublin 2

FOODMARBLE DIGESTIVE HEALTH LIMITED

CONTENTS

	Page
Special Auditors' Report	1 - 4
Abridged Statement of Financial Position	5 - 6
Statement of Changes in Equity	7
Notes to the Abridged Financial Statements	8 - 20

FOODMARBLE DIGESTIVE HEALTH LIMITED

**INDEPENDENT AUDITORS' SPECIAL REPORT TO THE MEMBERS OF FOODMARBLE DIGESTIVE
HEALTH LIMITED
PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

14 January 2026 | 09:24 GMT

On we reported as auditors of FoodMarble Digestive Health Limited to the directors of the Company on the abridged financial statements for the year ended 31 December 2024 on pages 5 to 20 and our report was as follows:

We have examined:

- (i) the abridged financial statements for the year ended 31 December 2024 on pages 5 to 20 which the directors of FoodMarble Digestive Health Limited propose to annex to the Annual Return of the Company; and
- (ii) the financial statements to be laid before the Annual General Meeting which form the basis for those abridged financial statements.

Respective responsibilities of Directors and Auditors

It is your responsibility to prepare the abridged financial statements which comply with the Companies Act 2014. It is our responsibility to form an independent opinion that the directors are entitled under Section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of the Company and that those abridged financial statements have been properly prepared pursuant to Section 353 of that Act (exemptions available for small companies) and to report our opinion to you.

This report is made solely to the directors in accordance with Section 356 of the Companies Act 2014. Our work was undertaken so that we might state to the directors those matters we are required to state to them in our report under Section 356 of the Companies Act 2014 and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the directors for our work, for this report, or for the opinions we have formed.

Basis of opinion

We have carried out the procedures we consider necessary to confirm, by reference to the financial statements, that the Company is entitled to annex abridged financial statements to the Annual Return of the Company and that the abridged financial statements are properly prepared. The scope of our work for the purpose of this report did not include examining or dealing with events after the date of our report on the full financial statements.

Opinion on financial statements

In our opinion the directors are entitled under Section 352 of the Companies Act 2014 to annex to the Annual Return of the Company the abridged financial statements and those abridged financial statements have been properly prepared pursuant to the provisions of Section 353 of that Act (exemptions available for small sized companies).

Other information

14 January 2026 | 09:24 GMT

On we reported as auditors of FoodMarble Digestive Health Limited to the members on the Company's financial statements for the year ended 31 December 2024 to be laid before its Annual General Meeting and our report was as follows:

FOODMARBLE DIGESTIVE HEALTH LIMITED

**INDEPENDENT AUDITORS' SPECIAL REPORT TO THE MEMBERS OF FOODMARBLE DIGESTIVE
HEALTH LIMITED (CONTINUED)
PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

"We have audited the financial statements of FoodMarble Digestive Health Limited (the 'Company') for the year ended 31 December 2024, which comprise the Statement of Financial Position, the Statement of Changes in Equity and the notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued in the United Kingdom by the Financial Reporting Council.

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the Company as at 31 December 2024 and of its loss for the year then ended;
- have been properly prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter

We draw attention to note 2.2 in the financial statements concerning the company's ability to continue as a going concern. The company incurred a loss for the year of €1,016,777 (2023: loss €334,131) and had net liabilities of €326,029 (2023: nets assets of €690,748) at the balance sheet date. The going concern assumption of the company is dependent on the company's ability in obtaining additional finance to meet the working capital needs for a period of not less than twelve months from the date of approval of the financial statements. These events and conditions, along with the other matters as set forth in note 2.2 to the financial statements, indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**INDEPENDENT AUDITORS' SPECIAL REPORT TO THE MEMBERS OF FOODMARBLE DIGESTIVE
HEALTH LIMITED (CONTINUED)
PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

Other information

The directors are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditors' report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited, and the financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities and restrictions on use**Responsibilities of directors**

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**INDEPENDENT AUDITORS' SPECIAL REPORT TO THE MEMBERS OF FOODMARBLE DIGESTIVE
HEALTH LIMITED (CONTINUED)
PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**


Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: <http://www.iaasa.ie>. This description forms part of our Auditors' Report."

The purpose of our audit work and to whom we owe our responsibilities

This report is made solely to the Company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

A6DAA001FDA5128...

Keith Doyle
for and on behalf of
Azets Audit Services Ireland Limited
3rd Floor
40 Mespil Road
Dublin 4
Date: 14 January 2026 | 09:24 GMT

FOODMARBLE DIGESTIVE HEALTH LIMITED

**ABRIDGED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024**

	Note	2024 €	2023 €
Fixed assets			
Intangible assets	8	1,628,692	1,464,627
Tangible assets	9	14,324	8,807
		<u>1,643,016</u>	<u>1,473,434</u>
Current assets			
Stocks		432,818	516,683
Debtors	10	651,651	627,275
Cash at bank and in hand		152,253	66,180
		<u>1,236,722</u>	<u>1,210,138</u>
Creditors: amounts falling due within one year	11	<u>(3,111,142)</u>	<u>(1,949,219)</u>
Net current liabilities		<u>(1,874,420)</u>	<u>(739,081)</u>
Total assets less current liabilities		<u>(231,404)</u>	<u>734,353</u>
Creditors: amounts falling due after more than one year	12	(94,625)	(43,605)
Net (liabilities)/assets		<u><u>(326,029)</u></u>	<u><u>690,748</u></u>
Capital and reserves			
Called up share capital presented as equity	13	12,638	12,638
Share premium account		6,447,966	6,447,966
Profit and loss account		(6,786,633)	(5,769,856)
Shareholders' deficit		<u><u>(326,029)</u></u>	<u><u>690,748</u></u>

FOODMARBLE DIGESTIVE HEALTH LIMITED


**ABRIDGED STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2024**

These financial statements have been prepared in accordance with the small companies regime.

We, as directors of FoodMarble Digestive Health Limited, state that:

The Company has relied on the specific exemptions contained in section 352 of the Companies Act 2014; the Company has done so on the grounds that it is entitled to the benefit of that exemption as a small Company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements were approved and authorised for issue by the board:



Aonghus Shortt
Director



Peter Harte
Director

Date: 09/Jan/2026

The notes on pages 8 to 20 form part of these financial statements.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Called up share capital	Share premium account	Profit and loss account	Total equity
	€	€	€	€
At 1 January 2024	12,638	6,447,966	(5,769,856)	690,748
Comprehensive income for the year				
Loss for the year	-	-	(1,016,777)	(1,016,777)
Total comprehensive income for the year	-	-	(1,016,777)	(1,016,777)
At 31 December 2024	12,638	6,447,966	(6,786,633)	(326,029)

The notes on pages 8 to 20 form part of these financial statements.

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Called up share capital	Share premium account	Profit and loss account	Total equity
	€	€	€	€
At 1 January 2023	12,638	6,249,143	(5,435,725)	826,056
Comprehensive income for the year				
Loss for the year	-	-	(334,131)	(334,131)
Total comprehensive income for the year	-	-	(334,131)	(334,131)
Shares issued during the year	-	198,823	-	198,823
At 31 December 2023	12,638	6,447,966	(5,769,856)	690,748

The notes on pages 8 to 20 form part of these financial statements.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

1. General information

These financial statements comprising the Statement of comprehensive income, the Balance sheet, the Statement of changes in equity and the related notes constitute the individual financial statements of FoodMarble Digestive Health Limited for the financial year ended 31 December 2024.

FoodMarble Digestive Health Limited is a company limited by shares incorporated in the Republic of Ireland. Guinness Enterprise Centre, Taylor's Lane, Dublin 8 is the registered office which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report.

2. Accounting policies**2.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2014 and the requirements of the Statement of Recommended Practice 'Accounting by Limited Liabilities Partnerships'. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

2.2 Going concern

The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for at least one year from the date of approval of these financial statements.

At 31 December 2024, the company had recorded a loss for the year of €1,016,777 and net liabilities totalled €326,029. The company's ability to continue as a going concern is dependant on the continued support of the company's shareholders. In this regard, the company has received confirmation from its shareholders indicating that, in so far as possible, they will continue to fund its future operations so that it can discharge its liabilities as they fall due for a period of at least one year from the date of the approval of these financial statements.

The directors have also considered the performance of the business subsequent to the year end together with future budgets and projected cashflows and are fully satisfied that the company will be profitable into the future.

On the basis of the foregoing the directors believe that it is appropriate for the financial statements to be prepared on the going concern basis. However, the financial statements do not include any adjustment that would result for a situation where financial support was no longer forthcoming for whatever reason, or where the company failed to achieve the projected financial results. The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for at least one year from the date of approval of these financial statements.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

2. Accounting policies (continued)**2.3 Foreign currency translation****Functional and presentation currency**

The Company's functional and presentational currency is Euros.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss Account within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

2.4 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

- the Company has transferred the significant risks and rewards of ownership to the buyer;
- the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

2. Accounting policies (continued)**2.5 Research and development**

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

2.6 Operating leases: The company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

2.7 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.8 Government Grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the Statement of comprehensive income in the same period as the related expenditure.

2.9 Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

2. Accounting policies (continued)**2.10 Pensions****Defined contribution pension plan**

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

2.11 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

2. Accounting policies (continued)

2.12 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

The estimated useful lives range as follows:

R&D Tooling	-	2	years
R&D App	-	5	years
Intellectual Property	-	10	years
R&D Device	-	4	years

2.13 Development costs

Development Expenditure is accounted for at cost less accumulated amortisation. This includes development expenditure on R&D Tooling, R&D App, Intellectual Property and R&D Device. Amortisation is calculated to write off the cost in equal annual instalments over their useful life.

2.14 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

At each reporting date the Company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

2. Accounting policies (continued)**2.14 Tangible fixed assets (continued)**

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Medical Equipment	-	33%
Computer equipment	-	33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.15 Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.16 Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.17 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.18 Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

3. Judgments in applying accounting policies and key sources of estimation uncertainty

Useful Lives of Intangible Fixed Assets

The annual amortisation charge depends primarily on the estimated lives of each type of asset and, in certain circumstances, estimates of residual values. The directors regularly review these useful lives and change them if necessary to reflect current conditions. In determining these useful lives management consider technological change, patterns of consumption and expected economic utilisation of the assets. Changes in the useful lives can have a significant impact on the amortisation charge for the financial year. The net book value of Intangible Fixed Assets subject to amortisation at the financial year end date was €1,628,691 (2023: €1,464,627).

4. Employees

The average monthly number of employees, including the directors, during the year was as follows:

	2024	<i>2023</i>
	No.	<i>No.</i>
Administration	3	<i>4</i>
Sales	6	<i>7</i>
Research & Development	16	<i>19</i>
	25	<i>30</i>

5. Directors' remuneration

	2024	<i>2023</i>
	€	<i>€</i>
Directors' emoluments	165,000	<i>226,441</i>
	165,000	<i>226,441</i>

Company has claimed exemption from disclosure of key management remuneration.

6. Interest payable and similar expenses

	2024	<i>2023</i>
	€	<i>€</i>
Interest payable to credit institutions	34,715	<i>42,025</i>
	34,715	<i>42,025</i>

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

7. Taxation

	2024	2023
	€	€
Corporation tax		
Current tax on profits for the year	(176,129)	(226,346)
	(176,129)	(226,346)
Total current tax	(176,129)	(226,346)
Deferred tax		
Total deferred tax	-	-
	(176,129)	(226,346)

Factors that may affect future tax charges

The company has estimated losses of €4,120,382 (2023: €3,332,797) available to carry forward against future trading profits.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

8. Intangible assets

	Patents €	R&D Device €	R&D Tooling €	R&D App €	Total €
Cost					
At 1 January 2024	63,274	2,758,674	129,855	52,820	3,004,623
Additions	-	721,418	-	-	721,418
At 31 December 2024	<u>63,274</u>	<u>3,480,092</u>	<u>129,855</u>	<u>52,820</u>	<u>3,726,041</u>
Amortisation					
At 1 January 2024	40,037	1,323,993	124,547	51,419	1,539,996
Charge for the year on owned assets	3,253	548,165	4,535	1,401	557,354
At 31 December 2024	<u>43,290</u>	<u>1,872,158</u>	<u>129,082</u>	<u>52,820</u>	<u>2,097,350</u>
Net book value					
At 31 December 2024	<u>19,984</u>	<u>1,607,934</u>	<u>773</u>	-	<u>1,628,691</u>
At 31 December 2023	<u>23,237</u>	<u>1,434,681</u>	<u>5,308</u>	<u>1,401</u>	<u>1,464,627</u>

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

9. Tangible fixed assets

	Medical equipment €	Computer equipment €	Total €
Cost or valuation			
At 1 January 2024	14,674	79,611	94,285
Additions	-	12,583	12,583
At 31 December 2024	<u>14,674</u>	<u>92,194</u>	<u>106,868</u>
Depreciation			
At 1 January 2024	14,674	70,804	85,478
Charge for the year on owned assets	-	7,066	7,066
At 31 December 2024	<u>14,674</u>	<u>77,870</u>	<u>92,544</u>
Net book value			
At 31 December 2024	<u>-</u>	<u>14,324</u>	<u>14,324</u>
<i>At 31 December 2023</i>	<u>-</u>	<u>8,807</u>	<u>8,807</u>

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

10. Debtors

	2024 €	2023 €
Trade debtors	191,033	142,573
Corporation tax repayable	407,504	417,369
Prepayments	3,000	5,136
Other debtors	1,440	1,440
VAT repayable	48,674	60,757
	<u>651,651</u>	<u>627,275</u>

11. Creditors: Amounts falling due within one year

	2024 €	2023 €
Overdrafts owed to credit institutions	27,288	61,335
Loans owed to credit institutions	110,779	149,750
Other loans	1,481,096	381,096
Trade creditors	577,271	407,679
Taxation and social insurance	687,418	740,110
Other creditors	51,107	45,644
Accruals	176,183	163,605
	<u>3,111,142</u>	<u>1,949,219</u>

12. Creditors: Amounts falling due after more than one year

	2024 €	2023 €
Loans owed to credit institutions	94,625	43,605
	<u>94,625</u>	<u>43,605</u>

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

13. Share capital

	2024 €	2023 €
Authorised		
999,924,354 (2023 - 999,924,354) Ordinary shares of €0.001 each	999,924	999,924
75,646 (2023 - 75,646) B Ordinary shares of €0.001 each	76	76
100,000,000 (2023 - 100,000,000) Preference shares shares of €0.001 each	100,000	100,000
400,000 (2023 - 400,000) 8% Cumulative Redeemable Convertible Preferences Shares shares of €0.001 each	400	400
748,656 (2023 - 748,656) C Ordinary shares shares of €0.001 each	749	749
	1,101,149	1,101,149
	1,101,149	1,101,149
Allotted, called up and fully paid		
4,037,000 (2023 - 4,037,000) Ordinary shares of €0.001 each	4,037	4,037
75,646 (2023 - 75,646) B Ordinary shares of €0.001 each	76	76
7,776,194 (2023 - 7,776,194) Preference shares shares of €0.001 each	7,776	7,776
748,656 (2023 - 748,656) C Ordinary shares shares of €0.001 each	749	749
	12,638	12,638
	12,638	12,638

Ordinary Shares means the ordinary shares of €0.001 each in the capital of the Company with voting rights.

B Ordinary Shares means the non-voting "B" ordinary shares of €0.001 each in the capital of the Company.

Preferred Shares means the preferred ordinary shares of €0.001 each in the capital of the Company with voting rights.

C Ordinary Shares means the non-voting "C" ordinary shares of €0.001 each in the capital of the Company.

Ordinary Shares means the ordinary shares of €0.001 each in the capital of the Company with voting rights.

B Ordinary Shares means the non-voting "B" ordinary shares of €0.001 each in the capital of the Company.

Preferred Shares means the preferred ordinary shares of €0.001 each in the capital of the Company with voting rights.

C Ordinary Shares means the non-voting "C" ordinary shares of €0.001 each in the capital of the Company.

FOODMARBLE DIGESTIVE HEALTH LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

14. ESOP shares

The Company has a Employee Share Option Pool (ESOP) of 1,389,452 share options. These options are to be set aside for selected employees, contractors, and directors. As of 31st December 2024 the directors have allocated a total of 909,225 (65%) of these share options to certain individuals, in their employment/consulting contracts.

15. Related party transactions

The Company has availed of the exemption provided in FRS 102, Section 33, "Related Party Disclosures", not to disclose transactions entered into with fellow group companies that are wholly owned within the group of companies of which the company is a wholly owned member.

16. Post balance sheet events

There are no significant post balance sheet events that require disclosure.

17. Controlling party

The Company is controlled by its shareholders and directors.

18. Approval of financial statements

The board of directors approved these financial statements for issue on 18 December 2025.

Title	[For signature] 2024 statutory accounts
File name	FoodMarble_Statut...024__abridged.pdf
Document ID	2cbb57cda4861b39d33b338888e086b74f017a41
Audit trail date format	MM / DD / YYYY
Status	● Signed

Document History



SENT

01 / 09 / 2026

12:03:27 UTC

Sent for signature to Peter Harte (peter@foodmarble.com) from aonghus@foodmarble.com
IP: 195.189.128.182



VIEWED

01 / 09 / 2026

12:03:57 UTC

Viewed by Peter Harte (peter@foodmarble.com)
IP: 193.189.66.150



SIGNED

01 / 09 / 2026

12:05:31 UTC

Signed by Peter Harte (peter@foodmarble.com)
IP: 193.189.66.150



COMPLETED

01 / 09 / 2026

12:05:31 UTC

The document has been completed.